Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Cash & Equivalents (2019 - 2025)

Burning Rock Biotech has reported Cash & Equivalents over the past 7 years, most recently at $67.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 6.8% year-over-year to $67.4 million; the TTM value through Dec 2025 reached $67.4 million, down 6.8%, while the annual FY2025 figure was $68.8 million, 3.83% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $67.4 million at Burning Rock Biotech, up from $65.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $322.5 million in Q1 2021 and troughed at $63.2 million in Q2 2025.
  • A 5-year average of $134.0 million and a median of $94.1 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 517.38% in 2021 and later tumbled 43.6% in 2022.
  • Year by year, Cash & Equivalents stood at $223.9 million in 2021, then crashed by 43.13% to $127.3 million in 2022, then crashed by 32.9% to $85.4 million in 2023, then decreased by 15.29% to $72.4 million in 2024, then fell by 6.8% to $67.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for BNR at $67.4 million in Q4 2025, $65.2 million in Q3 2025, and $63.2 million in Q2 2025.